Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2011 07:30 ET | Source: Gentium S.p.A.

Gentium Announces NDA Submission for Defibrotide

VILLA GUARDIA (COMO), Italy, July 6, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it has submitted a New Drug Application (NDA) to the United States Food...
June 21, 2011 07:30 ET | Source: Gentium S.p.A.

Gentium Signs License and Distribution Agreement for Defibrotide With Medison Pharma Ltd. in Israel and the Palestinian Authority

VILLA GUARDIA (COMO), Italy, June 21, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced that the Company has signed a ten-year exclusive license and distribution...
June 16, 2011 07:30 ET | Source: Gentium S.p.A.

Gentium Appoints Gen Ilac as Exclusive Distributor of Defibrotide in Turkey

VILLA GUARDIA (COMO), Italy, June 16, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced the appointment of Gen Ilac A.C. as exclusive distributor of Defibrotide in Turkey. Under the...
June 15, 2011 07:30 ET | Source: Gentium S.p.A.

Gentium Appoints Link Pharmaceuticals as Exclusive Distributor of Defibrotide in Australia and New Zealand

VILLA GUARDIA (COMO), Italy, June 15, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced the appointment of Link Pharmaceuticals as exclusive distributor of Defibrotide in Australia and...
June 01, 2011 07:30 ET | Source: Gentium S.p.A.

Gentium Announces MAA for Defibrotide Accepted by EMA and Will be Reviewed by CHMP Under Accelerated Assessment

VILLA GUARDIA (COMO), Italy, June 1, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that its Marketing Authorization Application (MAA) seeking approval of...
May 12, 2011 07:30 ET | Source: Gentium S.p.A.

Gentium Reports First Quarter Financial Results

Cash flow positive and stronger cash position Product sales of EUR 5.09 million Net income of EUR 1.70 million (US$ 2.42 million) VILLA GUARDIA (COMO), Italy, May 12, 2011 (GLOBE...
May 10, 2011 07:30 ET | Source: Gentium S.p.A.

Gentium Announces Submission of a Marketing Authorization Application for Defibrotide to the European Medicines Agency

VILLA GUARDIA (COMO), Italy, May 10, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced it has submitted a Marketing Authorization Application (MAA), under the...
April 05, 2011 07:30 ET | Source: Gentium S.p.A.

Gentium Hosts Symposium on Defibrotide at EBMT Annual Meeting and Sponsors Basic Science Award

VILLA GUARDIA (COMO), Italy, April 5, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the Company's lead product, Defibrotide, was the subject of a...
March 28, 2011 07:00 ET | Source: Gentium S.p.A.

Gentium Reports Fourth Quarter and Year End 2010 Financial Results

Defibrotide Phase 3 interim data presented at ASH from on-going Treatment IND shows significant increase in complete response and decrease in mortality On track to submit US and EU regulatory...
March 23, 2011 16:00 ET | Source: Gentium S.p.A.

Gentium to Review Fourth Quarter and Year End 2010 Financial Results

VILLA GUARDIA (COMO), Italy, March 23, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the Company will publish financials for the fourth quarter and year...